We are live on ! Find out more
EP

Eversept Partners Portfolio holdings

AUM $1.93B
1-Year Est. Return 160.8%
This Fund
S&P 500
This Quarter Est. Return
-7.76%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$1.41B
AUM Growth
+$104M
Cap. Flow
+$94.2M
Cap. Flow %
6.7%
Top 10 Hldgs %
55.6%
Holding
106
New
20
Increased
33
Reduced
17
Closed
29

Top Buys

Rank Stock Value
1
SNY icon
Sanofi
SNY
+$46.7M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$26.7M
3
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
+$26.5M
4
TNDM icon
Tandem Diabetes Care
TNDM
+$21M
5
ABMD
Abiomed Inc
ABMD
+$18.7M

Top Sells

Rank Stock Value
1
ASND icon
Ascendis Pharma A/S
ASND
+$49M
2
HCA icon
HCA Healthcare
HCA
+$27.9M
3
MASI
Masimo
MASI
+$27.2M
4
ARKG icon
ARK Genomic Revolution ETF
ARKG
+$21.6M
5
RCM
R1 RCM Inc. Common Stock
RCM
+$17.5M

Sector Composition

Rank Sector Weight
1 Healthcare 70.04%
2 Miscellaneous 29.08%
3 Industrials 0.88%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
GOSS icon
51
Gossamer Bio
GOSS
$83.2M
$3.92M 0.28%
468,303
+93,580
+25% +$725K
ANAB icon
52
AnaptysBio
ANAB
$1.67B
$3.71M 0.26%
182,717
+68,552
+60% +$1.52M
ARKK icon
53
PUT
ARK Innovation ETF
ARKK
$6.46B
$3.59M 0.26%
+90,000
New +$4.28M
IONS icon
54
Ionis Pharmaceuticals
IONS
$10.1B
$3.2M 0.23%
86,311
-72,495
-46% -$2.73M
AFMD
55
DELISTED
Affimed
AFMD
$3.13M 0.22%
+113,076
New +$3.87M
A icon
56
Agilent Technologies
A
$43.4B
$2.41M 0.17%
20,264
+1,009
+5% +$124K
ISRG icon
57
Intuitive Surgical
ISRG
$132B
$1.72M 0.12%
8,591
+428
+5% +$100K
CLDX icon
58
PUT
Celldex Therapeutics
CLDX
$3.07B
$1.63M 0.12%
+60,600
New +$1.76M
RVTY icon
59
Revvity
RVTY
$14.4B
$1.46M 0.1%
10,293
+505
+5% +$75.7K
IQV icon
60
IQVIA
IQV
$43.1B
$1.31M 0.09%
6,024
-53,546
-90% -$11.6M
LH icon
61
Labcorp
LH
$27.2B
$1.25M 0.09%
6,232
-37,895
-86% -$8.08M
WHWK
62
Whitehawk Therapeutics
WHWK
$263M
$1.24M 0.09%
100,817
-50,000
-33% -$743K
ICLR icon
63
Icon
ICLR
$13.1B
$1.21M 0.09%
5,587
-41,229
-88% -$9.25M
DXCM icon
64
DexCom
DXCM
$34.3B
$1.08M 0.08%
14,468
-99,148
-87% -$9.05M
ZNTL icon
65
Zentalis Pharmaceuticals
ZNTL
$360M
$1.08M 0.08%
38,342
-61,845
-62% -$1.64M
RGEN icon
66
Repligen
RGEN
$9.95B
$925K 0.07%
5,693
-30,828
-84% -$4.88M
MIST icon
67
Milestone Pharmaceuticals
MIST
$144M
$905K 0.06%
147,165
– –
MASI
68
DELISTED
Masimo
MASI
$782K 0.06%
5,984
-202,986
-97% -$27.2M
CYH icon
69
CALL
Community Health Systems
CYH
$413M
$750K 0.05%
+200,000
New +$1.41M
HSKA
70
DELISTED
Heska Corp
HSKA
$735K 0.05%
7,772
+1,936
+33% +$209K
TEVA icon
71
CALL
Teva Pharmaceuticals
TEVA
$42.5B
$699K 0.05%
92,900
– –
SWAV
72
DELISTED
Shockwave Medical, Inc. Common Stock
SWAV
$631K 0.04%
+3,300
New +$583K
ACIU icon
73
AC Immune
ACIU
$263M
$450K 0.03%
124,589
– –
SNDA icon
74
Sonida Senior Living
SNDA
$1.8B
$319K 0.02%
15,209
– –
ELDN icon
75
Eledon Pharmaceuticals
ELDN
$260M
$144K 0.01%
59,065
-54,943
-48% -$168K
1 2
3
4 5

Similar funds

SWM
Segment Wealth Management Houston, Texas $1.93B AUM 29.24% 1-Year Est. Return
RIA
Regal Investment Advisors Kentwood, Michigan $1.92B AUM 23.13% 1-Year Est. Return
SI
Standard Investments New York $1.93B AUM 6.23% 1-Year Est. Return
SG
Sourcerock Group Denver, Colorado $1.92B AUM 45.54% 1-Year Est. Return
DCP
Distillate Capital Partners Chicago, Illinois $1.92B AUM 5.31% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $1.93B AUM 134.74% 1-Year Est. Return
GIA
Guyasuta Investment Advisors Pittsburgh, Pennsylvania $1.94B AUM 32.92% 1-Year Est. Return
MFM
MHR Fund Management New York $1.92B AUM 119.57% 1-Year Est. Return

Eversept Partners's Q2 2022 Portfolio in Review

As of Q2 2022, Eversept Partners held 106 positions worth $1.41B, up 8% from $1.3B the previous quarter. Its ten largest holdings account for 56% of the portfolio.

Eversept Partners deployed $94.2M of net new capital in Q2 2022, opening 20 new positions and adding to 33 existing holdings. Its largest new stake was Sanofi: 879,460 shares worth $44M.

By sector, the portfolio is most concentrated in Healthcare at 70% of assets, down from 79% a quarter earlier, followed by Miscellaneous and Industrials.

On the sell side, the largest reduction was Masimo, an estimated $27.2M trimmed.

  • Eversept Partners's largest Q2 2022 buy was Sanofi: 879,460 shares worth $44M.
  • Eversept Partners added most to Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2022, an estimated $26.5M increase.
  • Eversept Partners's biggest Q2 2022 reduction was Masimo, cutting an estimated $27.2M.
  • Eversept Partners fully exited Ascendis Pharma A/S in Q2 2022, selling an estimated $49M.
  • Eversept Partners's ten largest holdings make up 56% of its $1.41B portfolio in Q2 2022.
  • Eversept Partners opened 20 new positions and closed 29 in Q2 2022.
  • Eversept Partners's portfolio value rose 8% quarter-over-quarter to $1.41B.

Based on Eversept Partners's 13F filing for Q2 2022, filed 15 Aug 2022.